BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 20842059)

  • 21. In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2.
    Berencsi K; Rani P; Zhang T; Gross L; Mastrangelo M; Meropol NJ; Herlyn D; Somasundaram R
    J Transl Med; 2011 Mar; 9():33. PubMed ID: 21450101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.
    Tanaka M; Tashiro H; Omer B; Lapteva N; Ando J; Ngo M; Mehta B; Dotti G; Kinchington PR; Leen AM; Rossig C; Rooney CM
    Clin Cancer Res; 2017 Jul; 23(14):3499-3509. PubMed ID: 28183713
    [No Abstract]   [Full Text] [Related]  

  • 23. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
    Andersch L; Radke J; Klaus A; Schwiebert S; Winkler A; Schumann E; Grunewald L; Zirngibl F; Flemmig C; Jensen MC; Rossig C; Joussen A; Henssen A; Eggert A; Schulte JH; Künkele A
    BMC Cancer; 2019 Sep; 19(1):895. PubMed ID: 31500597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
    Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS
    Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
    Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
    Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma.
    Liu G; Rui W; Zheng H; Huang D; Yu F; Zhang Y; Dong J; Zhao X; Lin X
    Eur J Immunol; 2020 May; 50(5):712-724. PubMed ID: 31981231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.
    Perna SK; Pagliara D; Mahendravada A; Liu H; Brenner MK; Savoldo B; Dotti G
    Clin Cancer Res; 2014 Jan; 20(1):131-9. PubMed ID: 24097874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma.
    Tumino N; Weber G; Besi F; Del Bufalo F; Bertaina V; Paci P; Quatrini L; Antonucci L; Sinibaldi M; Quintarelli C; Maggi E; De Angelis B; Locatelli F; Moretta L; Vacca P; Caruana I
    J Hematol Oncol; 2021 Nov; 14(1):191. PubMed ID: 34772439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
    Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A
    Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
    Klampatsa A; Achkova DY; Davies DM; Parente-Pereira AC; Woodman N; Rosekilly J; Osborne G; Thayaparan T; Bille A; Sheaf M; Spicer JF; King J; Maher J
    Cancer Lett; 2017 May; 393():52-59. PubMed ID: 28223167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes.
    Rossig C; Bollard CM; Nuchtern JG; Merchant DA; Brenner MK
    Int J Cancer; 2001 Oct; 94(2):228-36. PubMed ID: 11668503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
    Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
    BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
    Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
    Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression.
    Mueller KP; Piscopo NJ; Forsberg MH; Saraspe LA; Das A; Russell B; Smerchansky M; Cappabianca D; Shi L; Shankar K; Sarko L; Khajanchi N; La Vonne Denne N; Ramamurthy A; Ali A; Lazzarotto CR; Tsai SQ; Capitini CM; Saha K
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36382633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.
    Nishio N; Diaconu I; Liu H; Cerullo V; Caruana I; Hoyos V; Bouchier-Hayes L; Savoldo B; Dotti G
    Cancer Res; 2014 Sep; 74(18):5195-205. PubMed ID: 25060519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes.
    Hong H; Stastny M; Brown C; Chang WC; Ostberg JR; Forman SJ; Jensen MC
    J Immunother; 2014; 37(2):93-104. PubMed ID: 24509172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.
    Marin V; Dander E; Biagi E; Introna M; Fazio G; Biondi A; D'Amico G
    Exp Hematol; 2006 Sep; 34(9):1219-29. PubMed ID: 16939815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization.
    Grunewald L; Lam T; Andersch L; Klaus A; Schwiebert S; Winkler A; Gauert A; Heeren-Hagemann AI; Astrahantseff K; Klironomos F; Thomas A; Deubzer HE; Henssen AG; Eggert A; Schulte JH; Anders K; Kloke L; Künkele A
    Front Immunol; 2021; 12():689697. PubMed ID: 34267756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
    Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
    J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells.
    Halliwell E; Vitali A; Muller H; Alonso-Ferrero M; Barisa M; Gavriil A; Piapi A; Leboreiro-Babe C; Gileadi T; Yeung J; Pataillot-Meakin T; Fisher J; Tucker L; Donovan L; Chesler L; Chester K; Anderson J
    Cytotherapy; 2023 Jan; 25(1):46-58. PubMed ID: 36396552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.